News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Cosmo Pharmaceuticals S.p.A. to Launch Phase III Trails on Diarrhoea Drug Rifamycin
November 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH (Thomson Financial) - Cosmo Pharmaceuticals SpA said it is preparing phase III trails for its treatment for infectious diarrhoea, Rifamycin SV MMX, after previous trails proved successful.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
·
1 min read
·
BioSpace Insights
Gene therapy
Intellia’s CRISPR Gene Therapy Free To Move Forward After FDA Fully Lifts Hold
March 3, 2026
·
2 min read
·
Tristan Manalac
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
·
3 min read
·
Heather McKenzie
Rare disease
Aardvark Tanks After Pausing Prader-Willi Study on ‘Surprise’ Safety Signals
March 2, 2026
·
2 min read
·
Tristan Manalac
